One in seven Australian women are at risk of being diagnosed with breast cancer in their lifetime. Early detection is key for survival.
While mammograms have been around for more than three decades, Faculty of Medicine and Health researchers have been collaborating with Australian-based biotechnology company BCAL Diagnostics to revolutionise breast cancer diagnosis.
Sydney Mass Spectrometry (SydneyMS), a Core Research Facility based in the Kolling Institute and the Charles Perkins Centre, have been partnering with BCAL since 2017.
Using the cutting-edge technology available at SydneyMS, BCAL scientists discovered novel lipid biomarkers for breast cancer by Liquid Chromatography Mass Spectrometry (LCMS).
Members of the Faculty of Medicine and Health’s Sydney Medical School and School of Medical Sciences have been working with BCAL to make this possible:
- Professor Lisa Horvath (Sydney Medical School) is involved in the development of the test and is in discussions around clinical studies.
- Dr Dinny Graham (Sydney Medical School) has a biospecimen grant with Dr Amani Batarseh, Chief Scientific Officer at BCAL. Dr Graham and Dr Batarseh are collaborating on collecting samples out of Westmead.
- Associate Professor Sanjay Warrier (Sydney Medical School) is a clinical advisor to BCAL and has been collecting samples at Lifehouse with Dr Batarseh.
- Professor Jennifer Byrne (School of Medical Sciences) is the Director of Biobanking for NSW Health Pathology, who have granted BCAL funding.
- Dr Anthony Don (School of Medical Sciences) has provided advice on Lipidsearch and untargeted lipidomics
- Dr Kim Alexander (School of Medical Sciences) is involved in ongoing discussions and collaborations on lipids and brain cancer samples.
- Dr Georges Grau (School of Medical Sciences) co published with Dr Batarseh.
- Dr John O’Sullivan (School of Medical Sciences) helped BCAL with setting up their lipidomics examination and co-published with Dr Batarseh.
“The advancement of commercialisation for blood screening for breast cancer is a vital step in our ability to develop a suite of screening tools for early detection," said Professor Sarah Lewis, Associate Dean (Research Performance) in the Faculty of Medicine and Health,
"Industry and academia working together can accelerate translation and I am delighted that the Faculty of Medicine and Health is leading the way here.”
This collaboration and support from the Faculty of Medicine and Health has allowed BCAL to transition to a simplified, accredited examination that will form the basis of the new screening service and will be run in their newly opened lab.
Their aim is to get the blood test accredited and launched by 2024. The test has 91% sensitivity and 80% specificity. It is hoped to be a game changer when it comes to early detection.
The work expanded when BCAL further partnered with the Sydney Knowledge Hub in 2020, enabling them to have more staff on campus, and again in 2021 when the company made its Initial Public Offering which allowed them to expand the research program.
“The partnership with the University of Sydney had impacted the project on many levels," said Dr Amani Batarseh, Chief Scientific Officer at BCAL.
"From informal discussions with researchers like Dr Anthony Don on untargeted lipidomics to engagement with Dr Kim Alexander that could lead to new avenues of research on lipids and brain cancer.”.
https://news.google.com/rss/articles/CBMiigFodHRwczovL3d3dy5zeWRuZXkuZWR1LmF1L21lZGljaW5lLWhlYWx0aC9uZXdzLWFuZC1ldmVudHMvMjAyMy8wNy8wMy9jb2xsYWJvcmF0aW9uLXRvLWRldmVsb3AtbmV3LWJsb29kLXRlc3QtZm9yLWJyZWFzdC1jYW5jZXItZWFybHktLmh0bWzSAQA?oc=5
2023-07-03 04:02:54Z
CBMiigFodHRwczovL3d3dy5zeWRuZXkuZWR1LmF1L21lZGljaW5lLWhlYWx0aC9uZXdzLWFuZC1ldmVudHMvMjAyMy8wNy8wMy9jb2xsYWJvcmF0aW9uLXRvLWRldmVsb3AtbmV3LWJsb29kLXRlc3QtZm9yLWJyZWFzdC1jYW5jZXItZWFybHktLmh0bWzSAQA
Bagikan Berita Ini
0 Response to "Collaboration to develop new blood test for breast cancer early detection - University of Sydney"
Post a Comment